Humacyte (HUMA) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

HUMA Humacyte

Watchlist

5.495
+0.055+1.01%

Close Oct 1 16:00 ET

657.44MMarket Cap-4326P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Humacyte Price Target Maintained With a $25.00/Share by EF Hutton
Dow Jones15:59 ET · Ratings
Humacyte Is Maintained at Buy by EF Hutton
Dow Jones15:59 ET · Ratings
Humacyte to Participate in a Conference Call With Benchmark
TipRanksSep 30 15:55 ET
Analysts Conflicted on These Healthcare Names: Humacyte (HUMA) and Baxter International (BAX)
TipRanksSep 30 15:10 ET · Ratings
Humacyte, Inc. (HUMA) Increases Yet Falls Behind Market: What Investors Need to Know
Yahoo FinanceSep 26 18:15 ET
Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV) in Vascular Trauma Treatment on September 30, 2024
GlobeNewswireSep 26 17:26 ET

Comments

EZ_money

Sep 24 14:10

$Humacyte (HUMA.US)$ take profits to RR Richtech Robotics using a i Nvidia chip with a showing soon 🐂💥🚀📈

Flowerhill

Sep 24 13:28

$Humacyte (HUMA.US)$
+20% today 😃

Trytosaveabit

Sep 19 07:04

News

$Humacyte (HUMA.US)$ Reuters
1 min ago
Humacyte Announces Allowance of U.S. Patent Covering Biovascular Pancreas (Bvp™)

10baggerbamm

Aug 28 06:02

$Humacyte (HUMA.US)$ I know the news hasn't been superb, can always be better...
but the chart looks very very good here..
looks like 9+++ is coming
the options are spread too far apart if they had a $6 strike I think that would make the most sense but they have a 7.50 and to buy it at 60 cents would give you an 8.10 cost basis.. and if we see 9.50 which I think would be like a best case scenario that would yield a 1.40 so I don't think I don't think the options are a good play here because the...

Trytosaveabit

Aug 27 08:09

News

$Humacyte (HUMA.US)$ Humacyte Reports Positive Results From ATEV Treatment of Vascular Trauma in Ukraine
MT Newswires· 5 mins ago
Humacyte (HUMA) on Tuesday reported positive long-term results from its humanitarian program in Ukraine using the investigational acellular tissue engineered vessel, or ATEV, to treat severe vascular injuries.
The long-term data from the V017 trial showed 87.1% primary and secondary patency at 12 months. No infections, amputations, or deaths related to the ATEV wer...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

HUMA Humacyte

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target